oxybutynin hydrochloride.txt

CLINICAL USE

Urinary frequency, urgency and incontinenceNeurogenic bladder instability and nocturnal enuresis

DOSE IN NORMAL RENAL FUNCTION

2.5–5 mg 2 to 3 times a day; maximum 5 mg 4 times a dayXL: 5–20 mg once daily Patches: 1 patch (36 mg) twice weekly

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :393.9

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :83–85

%Excreted unchanged in urine &nbsp &nbsp : <0.1

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :193 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1.1–3 (XL: 12–13) /–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Dialysed. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsOther antimuscarinic agents: increased antimuscarinic effects

ADMINISTRATION

Reconstition

–

Route

Oral, topical

Rate of Administration

–

Comments

–

OTHER INFORMATION

Start with a low dose in elderly patients and those with renal impairment, and increase according to response

Tags: post-by-auto-php